Showing 4491-4500 of 4942 results for "".
- Actavis Divests Rights to Doryx to Mayne Pharmahttps://practicaldermatology.com/news/actavis-divests-rights-to-doryx-to-mayne-pharma/2459007/Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was
- Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North Americahttps://practicaldermatology.com/news/syneron-medical-appoints-william-griffing-to-newly-created-position-of-ceo-of-syneron-candela-north-america/2459009/Syneron Medical Ltd. appointed William Griffing to the newly created position of Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the Company's growth strategies for its North American
- Mikael Svensson Named Sr. VP of Sales/Marketing for Revision Skincarehttps://practicaldermatology.com/news/mikael-svensson-named-sr-vp-of-salesmarketing-for-revision-skincare/2459010/Revision Skincare appointed Mikael Svensson to the position of Senior Vice President of Sales and Marketing. In this new role, Mr. Svensson will oversee all Sales and Marketing activities, which include the strategic direction and leadership of Revis
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many
- Alphaeon Begins Phase III Study For Its Neurotoxin, Evosyalhttps://practicaldermatology.com/news/alphaeon-begins-phase-iii-study-for-its-neurotoxin-evosyal/2459018/The FDA agreed to Alphaeon® Corporations’s protocol for its Phase III clinical study of Evosyal™ to treat glabellar lines. Alphaeon acquired the exclusive US and certain international distribution rights to Evosyal, a botulinum toxin type A neuromodulator, as part of it
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- BioD Receives US Patent for Placental Tissue Technology for Improved Wound Care and Healinghttps://practicaldermatology.com/news/biod-receives-us-patent-for-placental-tissue-technology-for-improved-wound-care-and-healing/2459024/BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable T
- AARS Grant Application Deadline Approachinghttps://practicaldermatology.com/news/aars-grant-application-deadline-approaching/2459031/The American Acne & Rosacea Society (AARS) offers Mentorship and Clinical Research Grants to assist committed, visionary professionals lead acne and rosacea research, practice and clinical science into the future. AARS has ext
- FDA Approves Galderma's Soolantra to Treat Rosaceahttps://practicaldermatology.com/news/fda-approves-galdermas-soolantra-for-rosacea/2459038/The FDA approved Galderma’s Soolantra (ivermectin) Cream 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. R Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are norma
- Gary D. Monheit, MD Wins Top ASDS Honorhttps://practicaldermatology.com/news/gary-d-monheit-md-wins-top-asds-honor/2459040/Gary D. Monheit, MD is the “very honored” 2014 recipient of the American Society for Dermatologic Surgery's highest honor: the Samuel J. Stegman, MD, Award for D